Interaction Checker

Interaksi Oktreotid

Oktreotid (Sandostatin, Bynfezia, Mycapssa) memiliki 125 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 0 mayor, 125 moderat, 0 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi moderat (125)

  • AkarbosaantidiabetesModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Alogliptinpenghambat DPP-4Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Alogliptin dan metforminpenghambat DPP-4Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Amlodipinpenghambat kanal kalsium dihidropiridinModerat

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Amlodipin dan atorvastatinpenghambat kanal kalsium dihidropiridinModerat

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Amlodipin dan benazeprilpenghambat kanal kalsium dihidropiridinModerat

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Amlodipin dan olmesartanpenghambat kanal kalsium dihidropiridinModerat

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Amlodipin dan valsartanpenghambat kanal kalsium dihidropiridinModerat

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Antasida (Tums, Maalox, Mylanta)Produk obat bebasModerat

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Asebutololpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Atenololpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Atenolol dan klortalidonpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Beksagliflozinpenghambat SGLT2Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Betaksololpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Bisoprololpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Bisoprolol dan hidroklorotiazidpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Brimonidin dan timololagonis alfa-adrenergikModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Bromokriptinagonis dopaminModerat

    Bromocriptine: dose adjustment of bromocriptine may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Dapagliflozinpenghambat SGLT2Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Dapagliflozin dan metforminpenghambat SGLT2Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Dekslansoprazolpenghambat pompa protonModerat

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Dekstrometorfan dan kuinidinobat serotonergikModerat

    Drugs Metabolized by CYP 450 Enzymes: concomitant use with other drugs mainly metabolized by CYP3A4 that have a narrow therapeutic index (e.g., quinidine) should be used with caution and increased monitoring may be required (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Desogestrel dan etinilestradiolkontrasepsi oralModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • Digoksinglikosida digitalisModerat

    Digoxin: exposure may be decreased and assessment of clinical response to digoxin should be performed (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumModerat

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Dorzolamid dan timololpenghambat karbonat anhidraseModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Drospirenon dan etinilestradiolkontrasepsi oralModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • Dulaglutidagonis reseptor GLP-1Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Eksenatidagonis reseptor GLP-1Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Empagliflozinpenghambat SGLT2Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Empagliflozin dan metforminpenghambat SGLT2Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Esmololpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Esomeprazolpenghambat pompa protonModerat

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (label Oktreotid, Interaksi obat)

  • EstradiolestrogenModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • Estradiol dan dienogestkontrasepsi oralModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • Estradiol dan noretisteronestrogenModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • Estrogen teresterifikasi dan metiltestosteronestrogenModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • Estrogen terkonjugasiestrogenModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • Estrogen terkonjugasi dan bazedoksifenestrogenModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • Etinodiol diasetat dan etinilestradiolkontrasepsi oralModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • Etonogestrel dan etinilestradiolestrogenModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • Famotidinpenghambat H2Moderat

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Felodipinpenghambat kanal kalsium dihidropiridinModerat

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

  • FulvestrantestrogenModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • GlibenklamidsulfonilureaModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Glibenklamid dan metforminsulfonilureaModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • GlimepiridsulfonilureaModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • GlipizidsulfonilureaModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Glipizid dan metforminsulfonilureaModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • GlukagonModerat

    Hyperglycemia and Hypoglycemia MYCAPSSA alters the balance between the counter-regulatory hormones, insulin, glucagon, and growth hormone, which may result in hypoglycemia, or hyperglycemia, or diabetes mellitus. (label Oktreotid, Peringatan dan perhatian)

  • Ibuprofen dan famotidinOAINSModerat

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Insulin aspartinsulinModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Insulin degludekinsulinModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Insulin detemirinsulinModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Insulin glargininsulinModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Insulin lisproinsulinModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Insulin reguler (manusia)insulinModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Isradipinpenghambat kanal kalsium dihidropiridinModerat

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Kanagliflozinpenghambat SGLT2Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Karvedilolpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • KuinidinantiaritmiaModerat

    Drugs Metabolized by CYP 450 Enzymes: concomitant use with other drugs mainly metabolized by CYP3A4 that have a narrow therapeutic index (e.g., quinidine) should be used with caution and increased monitoring may be required (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Labetalolpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Lansoprazolpenghambat pompa protonModerat

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (label Oktreotid, Interaksi obat)

  • LevonorgestrelprogestinModerat

    Levonorgestrel Clinical Impact: Concomitant administration of MYCAPSSA with levonorgestrel decreases levonorgestrel bioavailability [see Clinical Pharmacology (‎12.3) ] . (label Oktreotid, Interaksi obat)

  • Levonorgestrel dan etinilestradiolkontrasepsi oralModerat

    Levonorgestrel Clinical Impact: Concomitant administration of MYCAPSSA with levonorgestrel decreases levonorgestrel bioavailability [see Clinical Pharmacology (‎12.3) ] . (label Oktreotid, Interaksi obat)

  • Levotiroksinhormon tiroidModerat

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (label Oktreotid, Peringatan dan perhatian)

  • Levotiroksin dan liotironinhormon tiroidModerat

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (label Oktreotid, Peringatan dan perhatian)

  • Linagliptinpenghambat DPP-4Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Linagliptin dan metforminpenghambat DPP-4Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Liotironinhormon tiroidModerat

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (label Oktreotid, Peringatan dan perhatian)

  • Liraglutidagonis reseptor GLP-1Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Lisinoprilpenghambat ACEModerat

    Lisinopril: bioavailability may be increased, monitor patient's blood pressure and adjust dose of lisinopril if needed (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Lisinopril dan hidroklorotiazidpenghambat ACEModerat

    Lisinopril: bioavailability may be increased, monitor patient's blood pressure and adjust dose of lisinopril if needed (‎ 7 ). (label Oktreotid, Interaksi obat)

  • MedroksiprogesteronprogestinModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • MegestrolprogestinModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • MetforminbiguanidModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Metoprololpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Metoprolol dan hidroklorotiazidpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Mifepristonpenghambat CYP3A4Moderat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • MiglitolantidiabetesModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Nadololpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Naproksen dan esomeprazolOAINSModerat

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (label Oktreotid, Interaksi obat)

  • NateglinidmeglitinidModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Natrium bikarbonatantasidaModerat

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Nebivololpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Nifedipinpenghambat kanal kalsium dihidropiridinModerat

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Nikardipinpenghambat kanal kalsium dihidropiridinModerat

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Nimodipinpenghambat kanal kalsium dihidropiridinModerat

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Nisoldipinpenghambat kanal kalsium dihidropiridinModerat

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Nizatidinpenghambat H2Moderat

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Norelgestromin dan etinilestradiolestrogenModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • NoretisteronprogestinModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • Noretisteron dan etinilestradiolkontrasepsi oralModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • Norgestimat dan etinilestradiolkontrasepsi oralModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • Norgestrel dan etinilestradiolkontrasepsi oralModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Omeprazolpenghambat pompa protonModerat

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Omeprazol dan natrium bikarbonatpenghambat pompa protonModerat

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Pantoprazolpenghambat pompa protonModerat

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Pindololpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • PioglitazontiazolidindionModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Pioglitazon dan glimepiridtiazolidindionModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Pioglitazon dan metformintiazolidindionModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • ProgesteronprogestinModerat

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (label Oktreotid, Interaksi obat)

  • Propiltiourasilobat antitiroidModerat

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (label Oktreotid, Peringatan dan perhatian)

  • Propranololpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Rabeprazolpenghambat pompa protonModerat

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Ranitidinpenghambat H2Moderat

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (label Oktreotid, Interaksi obat)

  • RepaglinidmeglitinidModerat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Saksagliptinpenghambat DPP-4Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Saksagliptin dan metforminpenghambat DPP-4Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Semaglutidagonis reseptor GLP-1Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • SiklosporinimunosupresanModerat

    Cyclosporine : may have decreased bioavailability and require dose adjustment ( 7 ). (label Oktreotid, Interaksi obat)

  • Simetidinpenghambat H2Moderat

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Sitagliptinpenghambat DPP-4Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Sitagliptin dan metforminpenghambat DPP-4Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Sotalolpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Telmisartan dan amlodipinpenghambat reseptor angiotensin II (ARB)Moderat

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

  • TelotristatModerat

    Short-Acting Octreotide Concurrent administration of short-acting octreotide with Xermelo significantly decreased the systemic exposure of telotristat ethyl and telotristat, the active metabolite. (label Telotristat, Interaksi obat)

  • Teriparatidhormon tiroidModerat

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (label Oktreotid, Peringatan dan perhatian)

  • Tiamazolobat antitiroidModerat

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (label Oktreotid, Peringatan dan perhatian)

  • Timololpenyekat betaModerat

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (label Oktreotid, Peringatan dan perhatian)

  • Tirzepatidagonis reseptor GLP-1Moderat

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

  • Verapamilpenghambat kanal kalsiumModerat

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Vitamin B12Vitamin dan mineralModerat

    Change in vitamin B12 levels: Monitor vitamin B 12 levels during treatment ( 5.6 ). (label Oktreotid, Peringatan dan perhatian)

Periksa Oktreotid terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.